Regeneron Pharmaceuticals, Inc.
Regeneron Announces Third Quarter 2025 Financial Results and Business Update
Summary
Regeneron Pharmaceuticals, Inc. reported third quarter 2025 financial results with total revenues increasing 1% to $3.75 billion. GAAP net income was $1.46 billion, and non-GAAP net income was $1.287 billion. Key product sales included a 27% increase in Dupixent global net sales to $4.86 billion and a 10% increase in EYLEA HD U.S. net sales to $431 million. FDA approved Libtayo for high-risk adjuvant cutaneous squamous cell carcinoma (CSCC). Positive Phase 3 results were reported across multiple clinical trials, and settlements were reached in patent infringement litigation related to EYLEA biosimilar products.
Profitelligence Alerts
Get alerts for REGN
Be first to know when Regeneron Pharmaceuticals, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Official SEC Documents
Advertisement